The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00336466|
Recruitment Status : Completed
First Posted : June 13, 2006
Last Update Posted : November 27, 2007
Context: Neurocognitive dysfunction complicates coronary artery bypass graft surgery. Neurocognitive dysfunction is a measurable problem with thinking. Erythropoietin may be a neuroprotectant.
Objective: To investigate the feasibility and safety of three doses of human recombinant erythropoietin to reduce neurocognitive dysfunction in coronary artery bypass graft patients.
|Condition or disease||Intervention/treatment||Phase|
|Cardiac Surgery Brain Injury||Drug: Human recombinant erythropoietin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||32 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS): A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Clinical Trial.|
|Study Start Date :||September 2004|
|Estimated Study Completion Date :||May 2005|
- Incidence of Neurocognitive Dysfunction
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00336466
|Calgary, Alberta, Canada, T2N 2T9|
|Principal Investigator:||David Zygun, MD||University of Calgary and Calgary Health Region|